Long-term study of umbilical cord blood transplants from unrelated donors

You may qualify if

• Appropriate diagnosis: Patients must have a disease or syndrome amenable to therapy with hematopoietic stem cell transplantation. Diagnoses include, but are not limited to:; Congenital and Other Non-malignant Disorders:; Immunodeficiency disorders (e.g. Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome); Congenital hematopoietic stem cell defects (e.g. Chediak-Higashi Syndrome, Congenital Osteopetrosis, Osteogenesis Imperfecta); Metabolic disorders (e.g. Hurler's Syndrome); Severe aplastic anemia; High-Risk Leukemia:; Acute Myelogenous Leukemia; Refractory to standard induction therapy (more than 1 cycle required to achieve remission); Recurrent (in CR ≥ 2); Treatment-related AML or MDS; Evolved from myelodysplastic syndrome; Presence of FLT3 abnormalities; FAB M6 or M7; Adverse cytogenetics; Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia including T lymphoblastic leukemia:; Refractory to standard induction therapy (time to CR >4 weeks); Recurrent (in CR ≥ 2); WBC count >30,000/mcL at diagnosis; Age >30 at diagnosis; Adverse cytogenetics, such as t(9:22), t(1:19), t(4:11), and other MLL rearrangements.; Chronic Myelogenous Leukemia in accelerated phase or blast crisis; Biphenotypic or undifferentiated leukemia; Burkitt's leukemia or lymphoma; Lymphoma:; Large cell, Mantle cell, Hodgkin lymphoma refractory or recurrent, chemo-sensitive, and ineligible for an autologous stem cell transplant or previously treated with autologous SCT; Marginal zone or follicular lymphoma that is progressive after at least two prior therapies; Multiple Myeloma, recurrent following high-dose therapy and autologous SCT or ineligible for an autologous HSCT; Solid tumors, with efficacy of allogeneic HSCT demonstrated for the specific disease and disease status; Adequate organ function:; Cardiac - LVEF >45%, or shortening fraction >25%, Absence of congestive heart failure or conduction disturbances with high risk for sudden death; Pulmonary - DLCO (corrected for hemoglobin), FEV1 and FVC ≥ 50% predicted;; Renal - serum Cr < 1.5 times the upper limit of normal for age or GFR ≥ 50 ml/min/1.73m2; Hepatic - total bilirubin level < 2 times the upper limit of normal (except for patients with Gilbert's syndrome or hemolysis); if the primary disease process is causal, this criterion will be reconsidered. ALT, AST, and Alkaline phosphatase ≤ 5 times upper limit of normal.; Performance Status Karnofsky or Lansky score ≥ 70%.; Informed Consent must be obtained prior to initiating conditioning therapy.; Receipt of viable cord blood product(s), single or dual, must be confirmed with the stem cell processing laboratory prior to initiating conditioning therapy.

You can't join if

• Availability of 10/10 or 9/10 HLA-matched related or unrelated donor within a reasonable timeframe dictated by the clinical urgency of the transplant
• Autologous HSCT < 6 months prior to proposed UCB transplant
• Pregnant or breast feeding
• Current uncontrolled infection
• Evidence of HIV infection or positive HIV serology